1-) Ruchan Uslu and Benjamin Bonavida. Free radicals dependent and independent pathways of CDDP-mediated cytotoxicity and apoptosis in ovarian tumor cell lines. International Journal of Oncology, May; 6: 1003-1009, 1995. (40 puan)

2-) Ruchan Uslu, Anaheid Jewett, and Benjamin Bonavida. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-Fas antibody-mediated cytotoxicity and apoptosis. Gynecologic Oncology, Aug; 62 (2): 282-291, 1996.

3-) Ruchan Uslu and Benjamin Bonavida. Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both Tumor Necrosis-α and Cis-Diamminedichloroplatinum. Cancer, Feb 15; 77 (4): 725-732, 1996.

4-) Benjamin Bonavida, Jeff Safrit, Hideki Morimoto, Yoichi Mizutani, Ruchan Uslu, Nicolo Borsellino, Patrick Frost, Jonathan Berek, Arie Belldegrun, Jacob Zighelboim, Chuen Pei Ng and Shunsuke Mori. Cross-resistance of tumor cells to chemotherapy and immunotherapy: approaches to reverse resistance and implications in gene therapy (review). Oncology Reports, Suppl. 1, 1 Jan-Feb; 4: 201-205, 1997.

5-) Ruchan Uslu, Nicolo Borsellino, Patrick Frost, Hermes Garban, Chuen-Pei Ng, Yoichi Mizutani, Arie Belldegrun and Benjamin Bonavida. Chemosensitization of human prostate carcinoma cell lines to anti-Fas-mediated cytotoxicity and apoptosis. Clinical Cancer Research, Jun; 3 (6): 963-972, 1997.

6-) Ender Terzioglu, Cengiz Kirmaz, Ruchan Uslu, Aytül Sin, Ali Kokuludag, Hayriye Uzuner, Filiz Sebik and Tomris Kabakci. Superior vena cava syndrome together with multiple venous thrombosis in Behcet’s Disease (A case report). Clinical Rheumatology, 17 (2): 176-177, 1998.

7-) Selim Uzunoglu, Ruchan Uslu, Mahmut Tobu, Guray Saydam, Ender Terzioglu, Filiz Buyukkececi, Serdar Bedii Omay. Augmentation of methylprednisolone-induced differentiation of myeloid leukemia cells by serine/threonine protein phosphatase inhibitors. Leukemia Research, May; 23(5): 507-512, 1999.

8-) Cag Cal, Ruchan Uslu, Gurhan Gunaydin, Ceyhun Ozyurt, S. Bedii Omay. Doxazosin: A New Cytotoxic Agent for Prostate Cancer? British Journal of Urology Int., Apr; 85 (6): 672-675, 2000.

9-) H. Hakan Aydin, Nur Selvi, Güray Saydam, Mahmut Tobu, Selim Uzunoglu, Ruchan Uslu, Filiz Buyukkececi, Serdar B. Omay. Upregulation of serine/threonine protein phosphatase type 2A regulatory subunits during methylprednisolone-induced differentiation of leukemic HL-60 cells. Clinical and Labaratory Haematology, Oct; 22 (5): 271-274, 2000.

10-) Ulus Ali Sanli, Ruchan Uslu, Canfeza Sezgin, Bulent Karabulut, Erdem Goker. Docetaxel: A First Choice in the Management of Anthracycline-Resistant Metastatic Breast Cancer. Journal of B.U.ON, 5: 399-403, 2000.

11-) Ruchan Uslu, Ulus A. Sanli, Canfeza Sezgin, Bulent Karabulut, Serdar B. Omay, Erdem Goker. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clinical Cancer Research, Dec; 6: 4958-4964, 2000.

12-) Safak Yuksel, Guray Saydam, Ruchan Uslu, Ulus Ali Sanli, Ender Terzioglu, Filiz Buyukececi, Serdar Bedii Omay. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. Leukemia Research, Apr; 26(4): 391-398, 2002.

13-) Zuhal Parildar, Ruchan Uslu, Tijen Tanyalcin, Eker Doganavsargil, Fatma Kutay. The urinary excretion of glycosaminoglycans and heparan sulphate in lupus nephritis. Clinical Rheumatology Aug; 21(4): 284-288, 2002.

14-) Ulus Ali Sanli, Ruchan Uslu, Bulent Karabulut, Canfeza Sezgin, Guray Saydam, Serdar Bedii Omay, Erdem Goker. Which dosing scheme is suitable for the taxanes? An in vitro model. Archives of Pharmacal Research Aug; 25 (4): 550-5, 2002.

15-) Ulus Ali Sanli, Ruchan Uslu, Bulent Karabulut, Canfeza Sezgin, Nur Selvi, Hakan H. Aydın, Guray Saydam, Erdem Goker, Serdar Bedii Omay. Alterations in the activity and expression of serine/threonine protein phosphatases during all trans retinoic acid-induced apoptosis in breast cancer cells. Oncology Reports, Nov-Dec; 10(6): 2083-8, 2003.

16-) Gülperi Öktem, Bulent Karabulut, Nur Selvi, Canfeza Sezgin, Ulus Ali Sanli, Ruchan Uslu, Mine Ertem Yurtseven, Serdar Bedii Omay. Differential effects of doxorubicin and docetaxel on nitric oxide production and inducible nitric oxide synthase expression in MCF-7 human breast cancer cells. Oncology Research, 14: 381-386, 2004.

17-) Erdem Goker, Ulus Ali Sanli, Yildiray Yüzer, Ruchan Uslu, Bulent Karabulut, Ahmet Memis, Ahmet Coker, Ali Mentes. Bioembolisation for Unresectable Hepatocellular Carcinoma: Preliminary Results of a Translational Research Study. Journal of Experimental & Clinical Cancer Research, 23: 403-409, 2004.

18-) Ruchan Uslu, Ulus Ali Sanli, Yilmaz Dikmen, Bulent Karabulut, Aydin Ozsaran, Canfeza Sezgin, Gamze G. Muezzinoglu, Serdar B Omay, Erdem Goker. Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens. International Journal of Gynecologic Cancer, 15: 240 245, 2005.

19-) Canfeza Sezgin, Bulent Karabulut, Ruchan Uslu, Ulus Ali Sanli, Gamze Goksel, Osman Zekioglu, Necmettin Ozdemir, Erdem Goker. Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer. Journal of Chemotherapy, Feb; 17(1): 111-117, 2005.

20-) Bulent Karabulut, Canfeza Sezgin, Cosan M. Terek, Ruchan Uslu, Ulus Ali Sanli, Levent Akman, Aydin Özsaran, Yilmaz Dikmen, Erdem Göker. Topotecan in platinum-resistant epithelial ovarian cancer. Chemotherapy, Oct; 51(6): 347-51. Epub 2005 Oct 14, 2005.

21-) Canfeza Sezgin, Bulent Karabulut, Ruchan Uslu, Ulus Ali Sanli, Gamze Goksel, Yildiray Yüzer, Erdem Goker. Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors. Scandinavian Journal of Gastroenterology, Dec; 40(12): 1486-92, 2005.

22-) Terek, MC; Karabulut, B; Selvi, N; Akman, L; Karasulu, Y; Ozguney, I; Sanli, AU; Uslu, R; Ozsaran, A. Arsenic trioxide-loaded, microemulsion-enhanced cytotoxicity on MDAH 2774 ovarian carcinoma cell line. International Journal of Gynecological Cancer, Mar-Apr; 16(2): 532-537, 2006.

23-) Sanli UA, Karabulut B, Uslu R, Korkut M, Goker E. Single-agent irinotecan for recurrent/metastatic colorectal cancer: a retrospective analysis. Medicinal Principles and Practice, 15(4): 288-92, 2006.

24-) N. Askar, T. Cırpan, E. Toprak, B. Karabulut, N. Selvı, M.C. Terek, R. Uslu, U.A. Sanlı & E. Goker. Arsenic trioxide exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicity. International Journal of Gynecological Cancer, Jul-Aug; 16(4): 1552-6, 2006.

25-) Goksel G, Taneli F, Uslu R, Ulman C, Dinc G, Coskun T, Kandiloglu AR. Serum her-2/neu and survivin levels and their relationship to histological parameters in early-stage breast cancer. Journal of International Medical Research, Mar-Apr; 35(2): 165-72, 2007.

26-) Saydam BK, Goksel G, Korkmaz E, Kapkac M, Ozdemir N, Sezgin C, Uslu R. Comparison of the clinical and pathological features between patients with recurrent metastatic breast carcinoma and patients with initially metastatic breast carcinoma. Saudi Medical Journal, Jan; 29(1): 81-6, 2008.

27-) Kucukzeybek Y, Gorumlu G, Karaca B, Erten C, Cengiz E, Kemal Gul M, Karabulut B, Uslu R, Sanli UA, Goker E. Docetaxel and platinum combination chemotherapy in locally advanced or metastatic head and neck cancer. Journal of B.U.ON Apr-Jun; 13(2): 199-203, 2008.

28-) Kucukzeybek Y, Gul MK, Cengiz E, Erten C, Karaca B, Gorumlu G, Atmaca H, Uzunoglu S, Karabulut B, Sanli UA and Uslu R. Enhancement of Docetaxel-Induced Cytotoxicity and Apoptosis by All-Trans Retinoic Acid (ATRA) Through Downregulation of Survivin (Birc5), Mcl-1 and Ltbeta-R in Hormone- and Drug Resistant Prostate Cancer Cell Line, DU145. Journal of Experimental& Clinical Cancer Research, Sep 12; 27(1): 37, 2008

29-) Saydam BK, Goksel G, Korkmaz E, Zekioglu O, Kapkac M, Sanli UA, Uslu R, Sezgin C. Comparison of inflammatory breast cancer and noninflammatory breast cancer in Western Turkey. Medicinal Principles and Practice, 17(6): 475-80, 2008.

30-) Gorumlu G, Kucukzeybek Y, Kemal Gul M, Karaca B, Terek M. Cosan, Karabulut B, Sanli UA, Akman L, Ozsaran A, Dikmen Y, Uslu R. Pegylated liposomal doxorubucin in heavily pretreated epithelial ovarian cancer patients. Journal of B.U.ON, Jul-Sep; 13(3): 349-352, 2008.

31-) Karaca B, Kucukzeybek Y, Gorumlu G, Erten C, Gul MK, Cengiz E, Atmaca H, Uzunoglu S, Sanli UA, Karabulut B, Uslu R. Profiling of angiogenic cytokines produced by hormone- and drug-refractory prostate cancer cell lines, PC-3 and DU-145 before and after treatment with gossypol. European Cytokine Network, Dec; 19 (4): 176-84, 2008.

32-) Karabulut B, Erten C, Gul MK, Cengiz E, Karaca B, Kucukzeybek Y, Gorumlu G, Atmaca H, Uzunoglu S, Sanli UA, Baran Y, Uslu R. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biology International, Feb; 33(2): 239-46, Epub 2008 Dec 11, 2009.

33-) Eyigor S, Karapolat H, Korkmaz OK, Eyigor C, Durmaz B, Uslu R, Uyar M. The frequency of fibromyalgia syndrome and quality of life in hospitalized cancer patients. European Journal of Cancer Care (Engl), Mar; 18(2): 195-201, 2009.

34-) Yasemin Yildirim, Ozen Onen Sertoz, Meltem Uyar, Cicek Fadiloglu, Ruchan Uslu. Hopelessness in Turkish cancer inpatients: The relation of hopelessness with psychological and disease-related outcomes. European Journal of Oncology Nursing Apr; 13(2): 81-6, Epub 2009 Feb 26, 2009.

35-) Cigdem Erten, Burcak Karaca, Yuksel Kucukzeybek, Gurbuz Gorumlu, Ercument Cengiz, Mustafa K. Gul, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus A. Sanli and Ruchan Uslu. Regulation of growth factors in hormone and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. British Journal of Urology International, Jul; 104(1): 107-14, Epub 2009 Feb 3, 2009.

36-) Ercument Cengiz, Burcak Karaca, Yuksel Kucukzeybek, Gurbuz Gorumlu, Mustafa K. Gul, Cigdem Erten, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus A. Sanli, Ruchan Uslu. Overcoming drug resistance in hormone-and drug refractory prostate cancer cell line, PC-3 by a synergistic combination of docetaxel and gossypol. Molecular Biology Reports, 2010 Mar;37(3):1269-77. Epub 2009 Mar 14.

37-) Degirmenci M, Karaca B, Gorumlu G, Durusoy R, Demir Piskin G, Bozkurt MT, Cirak Y, Tunali D, Karabulut B, Sanli UA, Uslu R. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. Medical Oncology 2010 Sep;27(3):585-91. Epub 2009 Jun 13.

38-) Yurekli BS, Karaca B, Cetinkalp S, Uslu R. Is it the time for metformin to take place in adjuvant treatment of Her-2 positive breast cancer? Teaching new tricks to old dogs. Medical Hypotheses, Oct; 73(4): 606-7. Epub 2009 Jun 27, 2009.

39-) Yurekli B, Karaca B, Cetinkalp S, Saygili F, Uslu R. Can gossypol be a hope for transsexual patients (male to female) before sex reassignment surgery? Just for adjusting the body to mind. Medical Hypotheses, Oct; 73(4): 625-6, Epub 2009 Aug 3, 2009.

40-) Sanli UA, Gorumlu G, Erten C, Gul MK, Cengiz E, Kucukzeybek Y, Karaca B, Atmaca H, Uzunoglu S, Karabulut B, Uslu R. Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination. Cell Biology International Nov;33(11):1165-72. Epub 2009 Aug 28, [Epub ahead of print], 2009.

41-) Demirci S, Yildirim YK, Ozsaran Z, Uslu R, Yalman D, Aras AB. Evaluation of burnout syndrome in oncology employees. Medical Oncology, 2010 Sep;27(3):968-74, Sep 26. [Epub ahead of print] 2009.

42-) Burcak Karaca, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus A. Sanli, Ruchan Uslu. Enhancement of taxane-induced cytotoxicity and apoptosis by gossypol in human breast cancer cell line, MCF-7. Journal of B.U.ON, Jul-Sep;14(3):479-85, 2009.

43-) Atmaca H, Gorumlu G, Karaca B, Degirmenci M, Tunali D, Purcu DU, Uzunoglu S, Karabulut B, Sanli UA, Uslu R. Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells. European Cytokine Network, Sep;20(3):121-30, 2009.

44-) Eyigor S, Eyigor C, Uslu R. Assessment of pain, fatigue, sleep and quality of life (QoL) in elderly hospitalized cancer patients. Archives of Gerontology and Geriatrics, Nov-Dec;51(3):e57-61, 2010. Epub Dec 30, 2009.

45-) S. Eyigor, H. Karapolat, O.K. Korkmaz, R. Uslu. The level of satisfaction in cancer patients with completed treatments: A 7-year screening. Journal of B.U.ON, 14: 681-687, 2009.

46-) Yüksel Küçükzeybek, Gürbüz Görümlü, Şaziye Burçak Karaca, Ali Can Kazandi, Bülent Karabulut, Rüçhan Uslu, Ulus Ali Şanli, Erdem Göker. Trastuzumab Induced Maculopapular Skin Reactions Localized on the Left Forearm and Arm: A Case Report. Turkiye Klinikleri J Med Sci, 29(6): 1743-6, 2009.

47-) Bulent Karabulut, Burcak Karaca, Harika Atmaca, Asli Kisim, Selim Uzunoglu, Canfeza Sezgin, Ruchan Uslu. Regulation of Apoptosis- Related Molecules by Synergistic Combination of All-Trans Retinoic Acid (ATRA) and Zoledronic Acid in Hormone-Refractory Prostate Cancer Cell Lines. Molecular Biology Reports, 2011 Jan; 38(1):249-59, Mar 28, 2010 [Epub ahead of print].

48-) Eyigor S, Karapolat H, Yesil H, Uslu R, Durmaz B. Effects of pilates exercises on functional capacity, flexibility, fatigue, depression and quality of life in female breast cancer patients: a randomized controlled study. Eur J Phys Rehabil Med. 2010 Dec; 46 (4): 481-7, May 6, 2010 [Epub ahead of print].

49-) Bulent Karabulut, Burcak Karaca, Umut Varol, Ugur Muslu, Burcu Cakar, Harika Atmaca, Asli Kisim, Selim Uzunoglu and Ruchan Uslu. Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer. Journal of Experimental & Clinical Cancer Research, Jul 30;29:102, 2010.

50-) Selim Uzunoglu, Burcak Karaca, Harika Atmaca, Asli Kisim, Canfeza Sezgin, Bulent Karabulut, Ruchan Uslu. Comparison of XTT and Alamar blue assays in the assessment of the viability of various human cancer cell lines by AT-101 (-/- gossypol). Toxicology Mechanisms and Methods, 20(8): 482–486, 2010.

51-) Ruchan Uslu, Murat Kapkac, Burcak Karaca, Hakan Çamyar, Raika Durusoy, Necmettin Özdemir, Arif B. Aras, Aysenur Oktay, Hayal Ozkilic, Rasih Yilmaz. Screening for metastasis in primary breast cancer patients having four or more axillary lymph node involvement: is it really necessary? Journal of B.U.ON, 15(3): 561-567, 2010.

52-) Eyigor C, Karaca B, Kuzeyli-Yildirim Y, Uslu R, Uyar M, Coker A. Does the tumor localization in advanced pancreatic cancer have an influence on the management of symptoms and pain? Journal of B.U.ON, 15(3): 543-6, 2010.

53-) Yüksel Kucukzeybek, Gurbuz Gorumlu, Ercument Cengiz, Cigdem Erten, Burcak Karaca, M. Kemal Gul, Bulent Karabulut, Ulus A. Sanlı, Ruchan Uslu. Bisphosphonate (Zoledronic Acid) Associated Adverse Events: Single Center Experience. International Journal of Hematology and Oncology, 20 (3): 135-140, 2010.

54-) Yüksel Kucukzeybek, Gurbuz Gorumlu, Ercument Cengiz, Bulent Karabulut, Canfeza Sezgin, Harika Atmaca, Ulus A. Sanlı, Selim Uzunoglu, Ruchan Uslu. Apoptosis-mediated cytotoxic effects of ibandronic acid on hormone-and drug-refractory prostate cancer cells and human breast cancer cells. Journal of International Medical Research, 38 (5): 1663-1672, 2010.

55-) Ozlem Akagunduz, Burcak Karaca, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus Ali Sanli, Ayfer Haydaroglu, Ruchan Uslu. Radiosensitization of Hormone-Refractory Prostate Cancer Cells by Gossypol Treatment. Journal of B.U.ON, 15(4): 763-767, 2010.

56-) Duygu Unuvar Purcu, Burcak Karaca, Murat Kapkac, Necmettin Ozdemir, Selim Uzunoglu, Ruchan Uslu. High-Resolution Melting Analysis for Screening of Turkish Germline Mutations in BRCA1 and BRCA2. International Journal of Hematology and Oncology, 20 (4): 235-240, 2010.

57-) Canfeza Sezgin, Erhan Gokmen, Murat Kapkac, Osman Zekioglu, Mustafa Esassolak, Bulent Karabulut, Ulus Ali Sanli, Ruchan Uslu. p53 Protein Accumulation and Presence of Visceral Metastasis Are Independent Prognostic Factors for Survival in Patients with Metastatic Inflammatory Breast Carcinoma. Medicinal Principles and Practice, 20 (2): 159-64, 2011.

58-) Raika Durusoy, Burcak Karaca, Bermet Junushova, Ruchan Uslu. Cancer patients' satisfaction with doctors and preferences about death in a university hospital in Turkey. Patient Education and Counseling, 85(3): e285-90, 2011.

59-) Cakar B, Muslu U, Karaca B, Junushova B, Uslu R, Goker E. Alveolar rhabdomyosarcoma originating from the uterine cervix. European Journal Of Gynaecological Oncology, 32 (2): 196-198, 2011.

60-) Selim Uzunoglu, Burçak Karaca, Harika Atmaca, Aslı Kisim, Bulent Karabulut, Ruchan Uslu. Targeting Bcl-2 Protein to Enhance Chemosensitivity of Hormone Refractory Prostate Cancer Cell Line, DU-145 by a Synergistic Combination of Docetaxel and Gossypol. Turkiye Klinikleri J Med Sci, 31(4):859-66, 2011.

61-) Yildirim Y, Tokem Y, Bozkurt N, Fadiloglu C, Uyar M, Uslu R. Reliability and validity of the Turkish version of the memorial symptom assessment scale in cancer patients. Asian Pac J Cancer Prev. 2011;12(12):3389-96.

62-) Kisim A, Atmaca H, Cakar B, Karabulut B, Sezgin C, Uzunoglu S, Uslu R, Karaca B. Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels. J Cancer Res Clin Oncol. 2012 Jul;138(7):1155-63. doi: 10.1007/s00432-012-1187-1. Epub 2012 Mar 13.

63-) Varol Y, Varol U, Karaca B, Karabulut B, Sezgin C, Uslu R. The Frequency and Significance of Radiologically Detected Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer. Med Princ Pract. 2012;21(5):457-61. doi: 10.1159/000337426. Epub 2012 Apr 27.

64-) Varol U, Karaca B, Muslu U, Doganay L, Degirmenci M, Uslu R, Goker E. Undifferentiated embryonal sarcoma of the liver in an adult patient: Case report. Turk J Gastroenterol. 2012 Jun;23(3):279-283.

65-) Bozkurt E, Atmaca H, Kisim A, Uzunoglu S, Uslu R, Karaca B. Effects of Thymus serpyllum Extract on Cell Proliferation, Apoptosis and Epigenetic Events in Human Breast Cancer Cells. Nutr Cancer. 2012 Nov;64(8):1245-50. doi: 10.1080/01635581.2012.719658.

66-) Cirak Y, Varol U, Atmaca H, Kisim A, Sezgin C, Karabulut B, Uzunoglu S, Uslu R, Karaca B. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A. BJU Int. 2012 Dec;110(11 Pt C):E1147-54. doi: 10.1111/j.1464-410X.2012.11392.x. Epub 2012 Aug 9.

67-) Arslan C, Uslu R. Secondary haematological malignancies in the BCIRG 001 study. Lancet Oncol. 2013 Mar;14(3):e87-8. doi: 10.1016/S1470-2045(13)70015-9. (Letter)

68-) Cirak Y, Sarsik B, Cakar B, Sen S, Simsir A, Uslu R. Predictive and prognostic values of Tau and BubR1 protein in prostate cancer and their relationship to the Gleason score. Med Oncol. 2013 Jun;30(2):526. doi: 10.1007/s12032-013-0526-7. Epub 2013 Mar 9.

69-) Ergun M, Eyigor S, Karaca B, Kisim A, Uslu R. Effects of exercise on angiogenesis and apoptosis-related molecules, quality of life, fatigue and depression in breast cancer patients. Eur J Cancer Care (Engl). 2013 Sep;22(5):626-37. doi: 10.1111/ecc.12068. Epub 2013 Jun 3.

70-) Harika Atmaca, Emir Bozkurt, Selim Uzunoglu, Ruchan Uslu, Burcak Karaca. A diverse induction of apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells. Toxicol Lett. 2013 Jun 20. doi:pii: S0378-4274(13)01076-X. 10.1016/j.toxlet.2013.06.213. [Epub ahead of print].

71-) Karaca B, Atmaca H, Bozkurt E, Kisim A, Uzunoglu S, Karabulut B, Sezgin C, Sanli UA, Uslu R. Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells. Mol Biol Rep. 2013 Jun;40(6):3925-33. doi: 10.1007/s11033-012-2469-z. Epub 2012 Dec 27.

72-) Cakar B, Varol U, Junushova B, Muslu U, Gursoy Oner P, Gokhan Surmeli Z, Cirak Y, Karaca B, Sezgin C, Karabulut B, Uslu R. Evaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer. J BUON. 2013 Apr-Jun;18(2):372-376.

73-) Varol U, Karaca B, Cakar B, Sezgin C, Karabulut B, Uslu R. Comparing Time to Disease Progression of Irinotecan and Oxaliplatin-based Chemotherapies in Colorectal Cancer Patients With Liver Only Metastasis. Am J Clin Oncol. 2013 Aug;36(4):388-91. doi: 10.1097/COC.0b013e318248da7c.

74-) Varol U, Cirak Y, Cakar B, Karaca B, Sezgin C, Uslu R, Karabulut B. Survival analysis of metastatic colorectal cancer patients who were treated with the five major therapeutic agents over the course of disease. J BUON. 2013 Jul-Sep;18(3):647-52.

75-) Korhan EA, Yildirim Y, Uyar M, Eyigör C, Uslu R. Examination of pain experiences of cancer patients in Western Turkey: a phenomenological study. Holist Nurs Pract. 2013 Nov-Dec;27(6):358-65. doi: 10.1097/HNP.0b013e3182a72b76.

76-) Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E, Buyukberber S, Camci C, Sencan O, Kilickap S, Ozdener F, Cevik D. Bevacizumab + Capecitabine as Maintenance Therapy after Initial Bevacizumab + XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase III 'Stop and Go' Study Results - A Turkish Oncology Group Trial. Oncology. 2013 Nov 12;85(6):328-335. [Epub ahead of print]

77-) Içli F, Altundağ K, Akbulut H, Paydaş S, Başaran G, Saip P, Doğu GG, Eralp Y, Uslu R, Sevinç A, Onur H, Mandel NM, Sezgin C, Altınbaş M, Güler N, Işıkdoğan A, Gökmen E, Uygun K, Ustüner Z, Yaren A, Demirkan B, Coşkun U, Ata A, Ozkan M, Arican A.Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG). Breast Cancer. 2015 Sep;22(5):480-5. doi: 10.1007/s12282-013-0506-y. Epub 2013 Dec 12.

78-) Cakar B, Karaca B, Uslu R. Sexual dysfunction in cancer patients: a review. J BUON. 2013 Oct-Dec;18(4):818-23.

79-) Varol U, Karaca B, Patır P, Sener A, Zekioglu O, Sanli UA, Uslu R. Association of Rac1 Expression with Trastuzumab Resistance in HER2-Positive Breast Cancer. International Journal of Hematology and Oncology, 23 (4): 219-226, 2013.

80-) Varol U, Oktay E, Yildirim M, Surmeli ZG, Dirican A, Meydan N, Karaca B, Karabulut B, Uslu R. Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first line treatment of metastatic colorectal cancer. Mol Clin Oncol. 2014 Jan;2(1):166-170. Epub 2013 Nov 12.

81-) Varol U, Yildiz I, Alacacioglu A, Uslu R. Anticancer Therapy for Breast Cancer Patients with Skin Metastases Refractory to Conventional Treatments. Asian Pac J Cancer Prev. 2014;15(4):1885-1887.

82-) Goksel G, Bilir A, Uslu R, Akbulut H, Guven U, Oktem G. WNT1 gene expression alters in heterogeneous population of prostate cancer cells; decreased expression pattern observed in CD133+/CD44+ prostate cancer stem cell spheroids. J BUON. 2014 Jan-Mar;19(1):207-14.

83-) Varol U, Dirican A, Yildiz I, Oktay E, Degirmenci M, Alacacioglu A, Barutca S, Karabulut B, Uslu R. First-line mono-chemotherapy in frail elderly patients with metastatic colorectal cancer. Asian Pac J Cancer Prev. 2014;15(7):3157-61.

84-) Ozcelik H, Cakmak DE, Fadiloglu C, Yildirim Y, Uslu R. Determining the satisfaction levels of the family members of patients with advanced-stage cancer. Palliat Support Care. 2015 Jun;13(3):741-7. doi: 10.1017/S1478951514000534. Epub 2014 Jun 3.

85-) Oktem G, Sercan O, Guven U, Uslu R, Uysal A, Goksel G, Ayla S, Bilir A. Cancer stem cell differentiation: TGFβ1 and versican may trigger molecules for the organization of tumor spheroids. Oncol Rep. 2014 Aug;32(2):641-9. doi: 10.3892/or.2014.3252. Epub 2014 Jun 12.

86-) Oktem G, Bilir A, Uslu R, Inan SV, Demiray SB, Atmaca H, Ayla S, Sercan O, Uysal A. Expression profiling of stem cell signaling alters with spheroid formation in CD133high/CD44high prostate cancer stem cells. Oncol Lett. 2014 Jun;7(6):2103-2109. Epub 2014 Mar 24.

87-) Goksel O, Goksel T, Cok G, Karakus H, Bacakoglu F, Goker E, Uslu R, Erdinc M. Hypersensitivity to chemotherapeutics: a cross sectional study with 35 desensitisations. Int J Clin Oncol. 2015 Apr;20(2):395-404. doi: 10.1007/s10147-014-0722-2. Epub 2014 Jul 25.

88-) Dirican A, Atmaca H, Bozkurt E, Erten C, Karaca B, Uslu R. Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway. Clin Transl Oncol. 2015 Feb;17(2):145-51. doi: 10.1007/s12094-014-1206-6. Epub 2014 Jul 25.

89-) Pivot X, Gligorov J, Müller V, Curigliano G, Knoop A, Verma S, Jenkins V, Scotto N, Osborne S, Fallowfield L; on behalf of the PrefHer Study Group; on behalf of the PrefHer Study Group. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014 Jul 28. pii: mdu364. [Epub ahead of print]

90-) Bayoglu IV, Varol U, Yildiz I, Muslu U, Alacacioglu A, Kucukzeybek Y, Akyol M, Demir L, Dirican A, Cokmert S, Yildiz Y, Karabulut B, Uslu R, Tarhan MO. Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer. Asian Pac J Cancer Prev. 2014;15(17):7119-23.

91-) Bicakli DH, Varol U, Degirmenci M, Tunali D, Cakar B, Durusoy R, Karaca B, Ali Sanli U, Uslu R. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract. 2016 Feb;22(1):46-53. doi: 10.1177/1078155214551315. Epub 2014 Sep 17.

92-) Varol U, Degirmenci M, Karaca B, Atmaca H, Kisim A, Uzunoglu S, Sezgin C, Sanli UA, Uslu R. Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines. Tumour Biol. 2015 Feb;36(2):779-86. doi: 10.1007/s13277-014-2682-6. Epub 2014 Oct 9.

93-) Varol U, Yildiz I, Salman T, Karabulut B, Uslu R. Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer. Tumori. 2014 Jul-Aug;100(4):370-6. doi: 10.1700/1636.17888. Review.

94-) Silbermann M, Fink RM, Min SJ, Mancuso MP, Brant J, Hajjar R, Al-Alfi N, Baider L, Turker I, ElShamy K, Ghrayeb I, Al-Jadiry M, Khader K, Kav S, Charalambous H, Uslu R, Kebudi R, Barsela G, Kuruku N, Mutafoglu K, Ozalp-Senel G, Oberman A, Kislev L, Khleif M, Keoppi N, Nestoros S, Abdalla RF, Rassouli M, Morag A, Sabar R, Nimri O, Al-Qadire M, Al-Khalaileh M, Tayyem M, Doumit M, Punjwani R, Rasheed O, Fallatah F, Can G, Ahmed J, Strode D. Evaluating Palliative Care Needs in Middle Eastern Countries. J Palliat Med. 2015 Jan;18(1):18-25. doi: 10.1089/jpm.2014.0194.

95-) Dirican A, Erten C, Atmaca H, Bozkurt E, Kucukzeybek Y, Varol U, Oktay Tarhan M, Karaca B, Uslu R. Enhanced cytotoxicity and apoptosis by thymoquinone in combination with zoledronic acid in hormone- and drug-resistant prostate cancer cell lines. J BUON. 2014 Oct-Dec;19(4):1055-1061.

96-) Varol U, Alacacioglu A, Yildiz I, Kucukzeybek Y, Uslu R. Gastric cancer with diffuse hepatic metastases and complete radiological response to triplet chemotherapy. J BUON. 2014 Oct-Dec;19(4):1128-1129.

97-) Karaca B, Degirmenci M, Ozveren A, Atmaca H, Bozkurt E, Karabulut B, Sanli UA, Uslu R. Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines. Cancer Chemother Pharmacol. 2015 Jun;75(6):1273-80. doi: 10.1007/s00280-015-2756-1. Epub 2015 Apr 30.

98-) Bicakli DH, Varol U, Degirmenci M, Tunali D, Cakar B, Durusoy R, Karaca B, Sanli UA, Uslu R. Reply To the Editor, Re: Bicakli et al. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract. 2015 Aug;21(4):318-9. doi: 10.1177/1078155215585051. Epub 2015 May 15.

99-) Varol U, Yildiz Y, Varol Y, Alacacioglu A, Uslu R. Importance of surveillance and risk factor evaluation in patients with multiple curable malignancies. Eur J Cancer Prev. 2015 Jul;24(4):363. (Letter)

100-) Cakar B, Muslu U, Erdogan AP, Ozisik M, Ozisik H, Tunakan Dalgic C, Durusoy R, Karaca B, Sezgin C, Karabulut B, Uslu R. The Role of Body Mass Index in Triple Negative Breast Cancer. Oncol Res Treat. 2015;38(10):518-22. doi: 10.1159/000439551. Epub 2015 Sep 11.

101-) Surmeli Z, Gursoy P, Erdogan AP, Bozkurt E, Atmaca H, Uzunoglu S, Sezgin C, Şanlı UA, Uslu R, Karaca B. Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway. Tumour Biol. 2016 Mar;37(3):3665-73. doi: 10.1007/s13277-015-3265-x. Epub 2015 Oct 13.

102-) Acikgoz E, Guven U, Duzagac F, Uslu R, Kara M, Soner BC, Oktem G. Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells. PLoS One. 2015 Oct 20;10(10):e0141090. doi: 10.1371/journal.pone.0141090. eCollection 2015.

103-) Degirmenci M, Erdogan AP, Bulut G, Atmaca H, Uzunoglu S, Karaca B, Karabulut B, Uslu R. Octreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells. Tumour Biol. 2016 Apr;37(4):4939-44. doi: 10.1007/s13277-015-4331-0. Epub 2015 Nov 3.

104-) Surmeli ZG, Varol U, Cakar B, Degirmenci M, Arslan C, Piskin GD, Zengel B, Karaca B, Sanli UA, Uslu R. Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer. Oncol Lett. 2015 Oct;10(4):2598-2602. Epub 2015 Jul 29.

105-) Ozcelik H, Guzel Y, Sonmez E, Aksoy F, Uslu R. Reliability and validity of the Turkish version of the EORTC QLQ-C15-PAL for patients with advanced cancer. Palliat Support Care. 2016 Dec;14(6):628-634. Epub 2016 Apr 12.

106-) Atmaca H, Bozkurt E, Kisim A, Uslu R. Comparative analysis of XTT assay and xCELLigence system by measuring cytotoxicity of resveratrol in human cancer cell lines. Turkish Journal of Biochemistry 2016, Volume 41(6): 413–421, DOI: https://doi.org/10.1515/tjb-2016-0128.

107-) Bulut G, Ozluk A, Erdogan AP, Uslu R, Elmas N, Karaca B. Pazopanib: a novel treatment option for aggressive fibromatosis. Clin Sarcoma Res. 2016 Dec 1;6:22. eCollection 2016.

108-) Hopanci Bicakli D, Ozkaya Akagunduz O, Meseri Dalak R, Esassolak M, Uslu R, Uyar M. The Effects of Compliance with Nutritional Counselling on Body Composition Parameters in Head and Neck Cancer Patients under Radiotherapy. J Nutr Metab. 2017;2017:8631945. doi: 10.1155/2017/8631945. Epub 2017 Jan 1.

109-) Yurekli BS, Karaca B, Kisim A, Bozkurt E, Atmaca H, Cetinkalp S, Ozgen G, Yilmaz C, Uzunoglu S, Uslu R, Saygili F. AT-101 acts as anti-proliferative and hormone suppressive agent in mouse pituitary corticotroph tumor cells. J Endocrinol Invest. 2018 Feb;41(2):233-240. doi: 10.1007/s40618-017-0733-8. Epub 2017 Jul 20.

110-) Yilmaz F, Soyer N, Uslu R, Erdogan AP, Karaca B, Saydam G, Sahin F, Vural F. Retrospective analysis of patients with relapsed or refractory testicular nonseminous germ cell tumors treated with autologous stem cell transplantation. Indian J Cancer. 2017 Apr-Jun;54(2):415-420. doi: 10.4103/ijc.IJC_284_17.

111-) Yilmaz F, Soyer N, Uslu R, Tobu M, Karaca B, Saydam G, Sahin F, Vural F. Risk factors for poor mobilization in solid tumors: How effectively can we mobilize patients with solid tumors? Transfus Apher Sci. 2017 Dec;56(6):809-813. doi: 10.1016/j.transci.2017.11.011. Epub 2017 Nov 8.

112-) Uskent N, Molinas Mandel N, Gulbas Z, Baloğlu G, Barkın B, Uslu R, Yazar A, Baloglu H. Cytolytic tests with hyperimmune patient sera is a good prognostic tool in racotumomab immunotherapy in advanced non-small cell lung cancer. Adv Mod Oncol Res 2017 Oct; 3(5): doi: 10.18282/amor.v3.i5.212.

113-) Erdem HA, Pullukçu H, Tasbakan M, Sipahi OR, Ulusoy S, Sertoz R, Uslu R, Yamazhan T. Follow-up of Chronic HBV Infected Patients Planned Chemotherapy Due to Solid Organ Malignancy. UHOD 2017, 27, 213-219.

114-) Hopancı Bıçaklı D, Ozveren A, Uslu R, Mederi Dalak R, Cehreli R, Uyar M, Karabulut B. The effect of chemotherapy on nutritional status and weakness in geriatric gastrointestinal system cancer patients. Nutrition. 2018 Mar;47:39-42. doi: 10.1016/j.nut.2017.09.013. Epub 2017 Oct 12.

115-) Yesil H, Eyigor S, Kayıkcıoglu M, Uslu R, Inbat M, Ozbay B. Is neuropathic pain associated with cardiac sympathovagal activity changes in patients with breast cancer? Neurol Res. 2018 Apr;40(4):297-302. doi: 10.1080/01616412.2018.1438225. Epub 2018 Feb 15.

116-) Yalcin S, Yildiz R, Dane F, Karaoğlu A, Oksuzoglu B, Ozyilkan O, Sevinc A, Ozdemir F, Turna H, Uslu R, Ulay E. A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey – NOTES study. OncoTargets and Therapy 2018, 11:1223-1228. doi: 10.2147/OTT.S148917.

117-) Eyigor S, Uslu R, Apaydın S, Caramat I, Yesil H. Can yoga have any effect on shoulder and arm pain and quality of life in patients with breast cancer? A randomized, controlled, single-blind trial. Complement Ther Clin Pract. 2018 Aug;32:40-45. doi: 10.1016/j.ctcp.2018.04.010. Epub 2018 Apr 30.

118-) Çakar B, Sürmeli Z, Öner PG, Yelim ES, Karabulut B, Uslu R. The Impact of Subtype Distribution in Inflammatory Breast Cancer Outcome. Eur J Breast Health. 2018 Oct 1;14(4):211-217. doi: 10.5152/ejbh.2018.4170. eCollection 2018 Oct.

119-) Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, Özgüroğlu M, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee JS, Calabrò L, Arén Frontera O, Ellers-Lenz B, Bajars M, Ruisi M, Park K. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018 Sep 21. pii: S1470-2045(18)30673-9. doi: 10.1016/S1470-2045(18)30673-9. [Epub ahead of print]

120-) von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5.

121-) Surmeli ZG, Ozveren A, Arslan C, Degirmenci M, Karaca B, Uslu R. Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma. Indian J Cancer. 2019 Jan-Mar;56(1):4-8. doi: 10.4103/ijc.IJC_355_18.

122-) Hopancı Bıçaklı D, Çehreli R, Özveren A, et al. Evaluation of sarcopenia, sarcopenic obesity, and phase angle in geriatric gastrointestinal cancer patients: before and after chemotherapy. Turk J Med Sci. 2019;49(2):583–588. Published 2019 Apr 18. doi:10.3906/sag-1808-114

123-) Oktay E, Yalcin GD, Ekmekci S, et al. Programmed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors. J BUON. 2019;24(2):779–790.

124-) Bicakli DH, Uslu R, Güney SC, Coker A. The Relationship Between Nutritional Status, Performance Status, and Survival Among Pancreatic Cancer Patients [published online ahead of print, 2019 Jul 4]. Nutr Cancer. 2019;1–7. doi:10.1080/01635581.2019.1634217.

125-) Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol. 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061.

126-) Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.

127-) Park K, Özgüroğlu M, Vansteenkiste J, Spigel D, Yang JCH, Ishii H, Garassino M, de Marinis F, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee JS, Calabrò L, Arén Frontera O, Xiong H, Bajars M, Ruisi M, Barlesi F. Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. J Thorac Oncol. 2021 Aug;16(8):1369-1378. doi: 10.1016/j.jtho.2021.03.009. Epub 2021 Apr 9.

128-) Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2.

129-) Bulut G, Guner Oytun M, Almuradova E, Harman M, Uslu R, Karabulut B. Contribution of "complete response to treatment" to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis. PLoS One. 2021 Nov 8;16(11):e0259622. doi: 10.1371/journal.pone.0259622. eCollection 2021.

130-) Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yañez E, Gümüş M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ; KEYNOTE-826 Investigators. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021 Nov 11;385(20):1856-1867. doi: 10.1056/NEJMoa2112435. Epub 2021 Sep 18.

131-) Bilici A, Uysal M, Menekse S, Akin S, Yildiz F, Turan M, Sezgin Goksu S, Beypinar I, Sakalar T, Değirmenci M, Erdem D, Basaran G, Olmez OF, Avci N, Tural D, Sakin A, Turker S, Demir A, Temiz S, Kaplan MA, Dogan M, Tanriverdi O, Bilgetekin I, Cinkir HY, Acikgoz O, Paydas S, Uslu R, Turhal S. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study. Cancer Invest. 2022 Feb;40(2):199-209. doi: 10.1080/07357907.2021.2017952. Epub 2021 Dec 22.

132-) Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651.

133-) Olmez OF, Bilici A, Er O, Bisgin A, Sevinc A, Akman T, Uslu R, Mandel NM, Yalcin S, Teomete M, Gorumlu G, Demir A, Namal E, Alici S, Selcukbiricik F, Bavbek S, Paksoy F, Basaran G, Ozer L, Sener N, Harputluoglu H; TUMPACT Study Group. Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours-results from a Turkish multi-centre study. Jpn J Clin Oncol. 2024 Jan 25:hyae002. doi: 10.1093/jjco/hyae002. Online ahead of print.